Condition: Huntington's Disease · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
This description comes directly from the study's public registry record.
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Edmonton, Canada | Recruiting |
| Clinical Trial Site | Montreal, Canada | Recruiting |
| Clinical Trial Site | Ottawa, Canada | Recruiting |
| Clinical Trial Site | Vancouver, Canada | Recruiting |
| Clinical Trial Site | Berlin, Germany | Recruiting |
| Clinical Trial Site | Bochum, Germany | Recruiting |
| Clinical Trial Site | Bonn, Germany | Recruiting |
| Clinical Trial Site | Dresden, Germany | Recruiting |
| Clinical Trial Site | Münster, Germany | Recruiting |
| Clinical Trial Site | Taufkirchen, Germany | Recruiting |
| Clinical Trial Site | Ulm, Germany | Recruiting |
| Clinical Trial Site | Birmingham, United Kingdom | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06585449